Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - Atenolol by AFT Pharmaceuticals Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted to regulate therapeutic goods in Australia, was introduced to ensure that the supply of therapeutic goods meets standards that protect public health and safety. One of the key functions of the Act is to provide mechanisms for the regulation of therapeutic goods, including the granting of consents for specific products that may not fully comply with certain regulations. This legislative framework is overseen by the Parliament of Australia and aims to balance the need for innovation and access to therapeutic goods with the imperative to protect public health. In the case of AFT Pharmaceuticals Pty Ltd, the delegate of the Secretary granted a consent under sections 14 and 14A of the Act to import atenolol in a non-compliant packaging format, subject to specific conditions designed to mitigate any potential risks to public safety. This action underscores the Act's role in facilitating access to essential medicines while enforcing stringent safety standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods, including medicines, medical devices, and blood and blood components, and it governs their import, supply, and manufacturing within Australia. This legislation, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, ensures that therapeutic goods meet quality, safety, and efficacy standards. The Act applies to a wide range of entities, including pharmaceutical companies, manufacturers, suppliers, and distributors of therapeutic goods. Its jurisdictional reach is national, as it applies to the entire Commonwealth of Australia, ensuring consistent regulation across states and territories. The Act allows for exceptions and exemptions, such as the consent granted to AFT Pharmaceuticals for the importation of atenolol under specific conditions, demonstrating the Act's flexibility in addressing particular circumstances while maintaining overarching regulatory standards. Subordinate instruments may further refine or extend the application of the Act, providing detailed guidelines and requirements for compliance.

Key Provisions

Under subsection 14 of the Therapeutic Goods Act 1989 (the Act), the Secretary of the Department of Health has the authority to provide consent for certain therapeutic goods that do not conform to specified regulatory standards. In this instance, section 14A of the Act allows the Secretary to grant a waiver to AFT Pharmaceuticals Pty Ltd, permitting them to import a specific batch of atenolol (Atenolol-AFT) 50 mg/10 mL oral solution bottles, which do not meet the child-resistant packaging requirements stipulated in Therapeutic Goods Order (TGO) No. 80. This consent was issued on August 18, 2014, and is effective from that date. The Act imposes several obligations on AFT Pharmaceuticals Pty Ltd in this context. Firstly, they must ensure that the atenolol product is repackaged into child-resistant containers before it is supplied to the market. This regulatory action must be undertaken and approved by the Therapeutic Goods Administration (TGA), demonstrating compliance with safety standards designed to prevent accidental ingestion by children. This requirement is crucial to mitigate any potential health risks associated with the non-compliant packaging. Failure to comply with the conditions set out in the consent may lead to significant legal consequences. While the Act does not explicitly enumerate offences or penalties related to this specific consent, breaches of the Therapeutic Goods Act generally may result in civil or criminal penalties. For instance, under section 36(1) of the Act, a corporation found guilty of an offence could face a substantial fine, with the maximum penalty reaching up to $2,100,000 for serious offences. Additionally, individuals responsible for the breach could face imprisonment or additional fines, depending on the severity and circumstances of the contravention. The consent granted under section 14A of the Act is thus not just a regulatory nod but a conditional permission that carries with it a responsibility to ensure public safety. By subjecting the consent to specific conditions, the Act underscores the importance of adhering to stringent safety standards, especially in the pharmaceutical industry where the consequences of non-compliance can be dire. This legislative framework is designed to protect the public, particularly vulnerable groups such as children, from the potential hazards associated with therapeutic goods that do not meet required standards.